PMA device
FRED X System
MicroVention, Inc. · Intracranial Aneurysm Flow Diverter (OUT, Class III) · First FDA decision Apr 26, 2022, newest Apr 26, 2022Brain aneurysm
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "FRED X"
MAUDE reports
7
Brand "FRED X", since 2015
PubMed studies
25
Mentioning "FRED X"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FRED X System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- FRED X SystemPMA supplement
P180027-S005 · Decided Apr 26, 2022 · 161 days after receipt · Normal 180 Day Track No User Fee
Device type: Intracranial aneurysm flow diverter (OUT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "FRED X", any status and sponsor, newest update first.
- MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval StudyActive, not recruiting
Microvention-Terumo, Inc.Public (4543.T)
NCT05409989 · 154 participants (planned) · Start Sep 20, 2022 · Primary completion Apr 2027
Device: FRED™ X™ · For: Intracranial Aneurysm
Sites: Hollywood, Florida; Orlando, Florida; Honolulu, Hawaii · 23 sites in all
- The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.Not yet recruiting
Jacobs instituteAcademic, hospital or other
NCT07761598 · 15 participants (planned) · Start Aug 2026 · Primary completion Dec 2028
Device: Fred X Medical Device Intervention for Aneurysm Treatment with DAPT Therapy. · For: Aneurysm Cerebral
Sites: Buffalo, New York
- FRED/ FRED Jr/ FRED X Intracranial Aneurysm Treatment StudyActive, not recruiting
Microvention-Terumo, Inc.Public (4543.T)
NCT03920358 · 156 participants · Start Apr 10, 2019 · Primary completion Jun 9, 2023
Device: FRED, FRED Jr and FRED X · For: Intracranial Aneurysm
Sites: Erlangen, Germany
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FRED X", and for the whole product code for context.
This brand
7 reports: 2 malfunction, 5 injury, 0 death
Whole product code OUT
10,961 reports: 7,308 malfunction, 3,152 injury, 499 death
Newest reports for this brand
- FRED-X 27Malfunction
2032493-2026-08027 · Received Jun 25, 2026 · Event dated May 5, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Material Deformation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FRED X 27Malfunction
2032493-2026-00376 · Received Jun 11, 2026 · Event dated May 18, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Collapse; Activation Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FRED-X 27Injury
2032493-2026-00271 · Received Apr 22, 2026 · Event dated Mar 31, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Structural Problem; Material Twisted/Bent
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0108-2026 · Started Sep 5, 2025 · Posted by FDA Oct 10, 2025
Reason given: Flow diverter may have a manufacturing issue related to the tantalum length and/or tantalum attachment pattern, which may lead the device to be incompletely open or not properly apposed to the vessel wall, which may necessitate device recapture and withdrawal of the delivery system and microcatheter together....
Cause as FDA categorized it: Device Design · Device type: Intracranial Aneurysm Flow Diverter (OUT)
Published research
The most relevant PubMed records for "FRED X"[tiab]. The summary above synthesizes these.
- The FRED-X Flow Diverter-An Australian Experience.
Tan PS, Li C, Williams C, et al. · J Med Imaging Radiat Oncol · 2025
- FRED X flow diversion stent for intracranial aneurysms: a systematic review and meta-analysis.
Mortezaei A, Essibayi MA, Ghorbi L, et al. · Neuroradiology · 2025Review
- Multicenter comparative analysis of FRED-X, pipeline shield, and surpass evolve in treating intracranial aneurysms.
Roy JM, Musmar B, Karadimas S, et al. · Interv Neuroradiol · 2025
- FRED X flow diversion stenting for unruptured intracranial aneurysms: US multicenter post-market study.
Hendrix P, Hemmer S, Sioutas GS, et al. · J Neurointerv Surg · 2025Multicenter Study
- FRED X flow diverter for the treatment of intracranial aneurysms: Two-center experience and mini-review of the literature.
Goertz L, Styczen H, Siebert E, et al. · Interv Neuroradiol · 2026Multicenter Study
- Safety and efficacy of coated flow diverters in the treatment of cerebral aneurysms during single antiplatelet therapy: A multicenter study.
Goertz L, Hohenstatt S, Vollherbst DF, et al. · Interv Neuroradiol · 2024Multicenter Study, Observational Study
- Use of flow-diverting stents in the treatment of ruptured intracranial artery dissections.
Afridi MO, Sozio SJ, Roychowdhury S, et al. · Surg Neurol Int · 2025Case Reports
- Comparative hemocompatibility assessment of fibrin/heparin-coated and PMEA-coated flow diverters.
Wei H, Riedel T, Riedelová Z, et al. · J Mater Sci Mater Med · 2026Comparative Study
- First United States multicenter experience with the new-generation FRED X surface-modified flow diversion stent: feasibility, safety, and short-term efficacy.
Abbas R, Lan M, Naamani KE, et al. · J Neurosurg · 2024Multicenter Study
- RECOAT study - Retrospective evaluation of surface-modified and coated flow diverters for the treatment of unruptured intracranial aneurysms.
Goertz L, Hohenstatt S, Vollherbst DF, et al. · Neuroradiology · 2026Multicenter Study
- Comparative analysis of safety and efficacy of flow diversion with and without surface modification technology, FRED-X, FRED, PED shield and PED in 386 patients: A single center experience with systematic review and network meta analysis.
Roy JM, Musmar B, El Naamani K, et al. · J Neurol Sci · 2025Systematic Review, Comparative Study
- Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.
Wen DW, Ayre J, Puthuran M, et al. · Clin Neuroradiol · 2025Multicenter Study
Other devices of this type
Also filed under product code OUT.
- Pipeline Flex Embolization Device with Shield TechnologyMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2021
- Flow Re-Direction Endoluminal Device (FRED®) SystemMicroVention, Inc. · PMA 2025
- Pipeline Embolization Devices,pipeline Flex Embolization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2015
- Pipeline Vantage Embolization Device with Shield TechnologyMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2025
- Surpass Streamline Flow DiverterStryker Neurovascular · PMA 2022
- Surpass Elite Flow Diverter SystemStryker Neurovascular · PMA 2024
- Surpass Evolve Flow Diverter SystemStryker Neurovascular · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.